| Contact Us | +41 21 691 43 75 | info@genepredictis.com | EPFL Innovation Park (bâtiment B) | 1015 Lausanne | Switzerland |
| Contact Us |
| +41 21 691 43 75 |
| info@genepredictis.com |
| EPFL Innovation Park (bâtiment B) |
| 1015 Lausanne |
| Switzerland |
~ OTHER PRODUCTS~
~ GENETICS ~
HLA-B27
Genetic test assessing the risk of developing certain autoimmune disorders such as ankylosing spondylitis, reactive arthritis (Reiter’s Syndrome), psoriatic arthritis, ulcerative colitis associated spondyloarthritis, anterior uveitis and iritis.
LACTOSE
Analysis of the genetic variant leading to lactose intolerance.
GLUTEN
A classical undiagnosed problem. Look for genetic variants linked to gluten impaired metabolisation.
FRUCTOSE
Analysis of the genetic variants described as risk factor for fructose intolerance.
HOMOCYSTEINE
Analysis of genetic variants in MTHFR gene associated with high homocysteine levels.
HEMOCHROMATOSIS
Analysis of the genetic variants responsible for familial hemochromatosis, severe metabolic disease, that is often overlooked.
FACTOR II
Analysis looking for presence of absence of Factor II-G20210A genetic variant, associated with increased risk of developing deep-vein thrombosis and pulmonary embolism.
FACTOR V-LEIDEN
Analysis searching for the presence of absence of Factor V-Leiden genetic variant, associated with increased risk of developing deep-vein thrombosis and pulmonary embolism.
~ PHARMACOGENETICS ~
GENES ENCODING ENZYMES OF PHASE I
Clinically relevant genetic variants in the following genes encoding enzymes of phase I of drug metabolism can be analysed individually or in combination:
P450 CYP 1A2, CYP 2A6, CYP 2B6, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1, CYP 3A4, CYP 3A5; BCHE, DPYD
GENES ENCODING ENZYMES OF PHASE II
Clinically relevant genetic variants in the following genes encoding enzymes of phase II of drug metabolism can be analysed individually or in combination:
NAT2, GSTM1, GSTT1, GSTP1, SULT1A1, UGT1A1, TPMT, COMT
GENES ENCODING TRANSPORTERS
Clinically relevant genetic variants in the following genes encoding drug transporters:
ABCB1 (MDR1), ABCG2, SLC19A1, SLC22A1
TPMT
Analysis of genetic variants associated with efficacy of Thiopurine treatment in autoimmune diseases or leukaemia.
GSTP1
Analysis of the relevant genetic variants in the GSTP1 gene, associated with chemotherapy response and adverse effects of cyclophosphamide, epirubicin, and oxaliplatine.
DPYD
Analysis of DPYD gene mutations associated with severe or lethal toxicity upon treatment with 5-fluorouracil (5-FU) or a widely prescribed oral fluoropyrimidine capecitabine (Xeloda).
TAMOXIFEN
Analysis of genetic variants predicting efficiency of Tamoxifen treatment.
IL28B
Analysis of gene variants that help predicting efficacy of combination antiviral therapy PEG-IFN alpha/RBV.
HLA-B*5701
Analysis of genetic variants associated with hypersensitivity to Abacavir treatment and Flucloxacillin-induced liver injury.
COAG
Analysis of genetic variants associated with efficacy and safety of coumarins.
CLOPIDOGREL
Analyses of the genetic variants associated with efficacy and safety of Clopidogrel.
CARBAMAZEPINE
Analyses of genetic variants associated with safety of Carbamazepine drug treatment
UGT1A1
Genetic analysis of UGT1A1 gene variants that predicts toxicity and treatment efficacy of Irinotecan treatment for metastatic colorectal cancer patients.
STATINS
Statins are among the most used drugs in Switzerland. They are proven very efficacious to lower blood lipid levels, notably “bad” cholesterol (from 30% to 50%), as well as to diminish cardiovascular disease and mortality in individuals at risk. However, their efficacy varies according to specific genetic variants present in the genome of the patient.
Unfortunately, statin treatments can also cause secondary effects and the most frequent ones involve mild to severe muscle pathologies (observed in 10 -15% of individuals treated with statins). The occurrence of secondary effects is influenced by age, BMI, type and dosage of statins, drug-drug interactions, but also by genetics.
Testing for genetic variants involved in the metabolism and toxicity of statins allows determining the most optimal treatment with fewer secondary effects.
Information for professionals (en)
Information for professionals (de)
From January 1st, 2018 Statins test is reimbursed by supplementary healthcare cover PRIMEO from Helsana and for all patients that have subscribed to the supplementary insurance PRIMEO and use statin drugs.
~ MULTIFACTORIAL DISEASES ~
GLAUCOMA
Analyses of mutations associated with exfoliation glaucoma.
AMD
Analyses of genetic variants associated with age-related macular degeneration.
EYES
Analysis of genetic variants associated with glaucoma and age-related macular degeneration (AMD). These diseases may ineluctably hamper eyesight performances before diagnosis is made.
OSTEO
Analysis of genetic variants in a number of genes associated to hormone receptors and skeletal proteins. A smart approach to fight one amongst the most prevalent “silent diseases” of the 21st century.
THROMBO E2 RISK
Analysis of genetic variants related to the risk of thrombosis under hormone replacement therapy. Using the proprietary algorithm, genetic and clinical risk factors are taken into account to quantify the risk.
CARDIO
Genetic test that allows to estimate risk of developping coagulation conditions, hypercholesterolemia, hypertension and cardiovascular diseases.
~ OTHERS ~
DETOX
Analysis of genetic variants that impact fuction of the major detoxification pathways; informs about the ability to detoxify diverse toxic substances and buffer oxidative stress.
BETTER AGEING
Many age-related diseases have as origin the interaction between the content of our genes and our lifestyle. Everyone does not fight with the same weapons against osteoporosis or cardiovascular disease. The knowledge of the content of our genes allows personalized medical treatments and enables disease prevention.
EXCLUSIVE
The test provides with a comprehensive view of the patient’s risk factors. It offers a unique opportunity to tailor therapeutic options, lifestyle choices, nutrition, and habits, according to unique sequences in patient’s genome, to maintain and improve his/her health capital.
WEIGHTPASS
The test is a comprehensive analysis of genetic variants that allow personalized recommendations concerning weight gain, weight loss and eventual regain, appetite control, food interactions and benefices of the physical exercise, altogether allowing to setup personalized weight-loss plan and to improve health and quality of life.
SPORT
A comprehensive genetic analysis that enables to adapt training, recovery and detoxification strategies after excercice to individual, with aim to improve sport performances.
SMILE
Genetic test that assesses risk of developing periodontitis.
NICOTINE
Genetic test that predicts the medication that will have the highest impact on success of quitting cigarettes smoking.
ALCOHOL
Analysis of the genetic variants involved in metabolism, addiction and detoxification of alcohol.